Michael Soyka, Gabi Koller, Wittchen Hans-Ulrich, Gerhard Bühringer
{"title":"阿片类激动剂治疗患者持续高比例的精神健康障碍——一项为期6年的纵向研究结果","authors":"Michael Soyka, Gabi Koller, Wittchen Hans-Ulrich, Gerhard Bühringer","doi":"10.1111/ajad.70085","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).</p><p><strong>Methods: </strong>Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).</p><p><strong>Results: </strong>The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).</p><p><strong>Conclusions and scientific significance: </strong>Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.</p>","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.\",\"authors\":\"Michael Soyka, Gabi Koller, Wittchen Hans-Ulrich, Gerhard Bühringer\",\"doi\":\"10.1111/ajad.70085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).</p><p><strong>Methods: </strong>Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).</p><p><strong>Results: </strong>The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).</p><p><strong>Conclusions and scientific significance: </strong>Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.</p>\",\"PeriodicalId\":7762,\"journal\":{\"name\":\"American Journal on Addictions\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal on Addictions\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajad.70085\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal on Addictions","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajad.70085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.
Background and objectives: There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).
Methods: Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).
Results: The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).
Conclusions and scientific significance: Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.
期刊介绍:
The American Journal on Addictions is the official journal of the American Academy of Addiction Psychiatry. The Academy encourages research on the etiology, prevention, identification, and treatment of substance abuse; thus, the journal provides a forum for the dissemination of information in the extensive field of addiction. Each issue of this publication covers a wide variety of topics ranging from codependence to genetics, epidemiology to dual diagnostics, etiology to neuroscience, and much more. Features of the journal, all written by experts in the field, include special overview articles, clinical or basic research papers, clinical updates, and book reviews within the area of addictions.